[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fphl1z6VJ-dzBSYMz91g8cv93YDanmhtqge2ImuDisxQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"University Hospital, Antwerp",[4],237,false,66,9,45583,21,179,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Obstructive Sleep Apnea",16,{"name":18,"count":19},"Tinnitus",8,{"name":21,"count":22},"Surgery",5,{"name":24,"count":22},"Multiple Sclerosis",{"name":26,"count":27},"Chronic Obstructive Pulmonary Disease",4,{"name":29,"count":27},"Type 1 Diabetes",{"name":31,"count":27},"Sleep Apnea",{"name":33,"count":34},"Respiration, Artificial",3,[36,41,46,50,55,60,65,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04227093","Acetazolamide Add-On Therapy to OSA Surgery","2023-04-22","Acetazolamide",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT02649582","Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients","2024-12","Dendritic cell vaccine plus temozolomide chemotherapy",{"nctId":47,"briefTitle":48,"date":44,"intervention":49},"NCT05506332","Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed\u002FRefractory Acute Myeloid Leukemia","Venetoclax",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05964361","First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients","2025-09-28","IL15-transpresenting WT1-targeted Dendritic Cell Vaccine",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT05765084","Integration of the PD-L1 Inhibitor Atezolizumab and WT1\u002FDC Vaccination Into Platinum\u002FPemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","2026-10","Dendritic cell vaccination",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05974462","MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)","2026-10-01","Methylprednisolone 125 MG",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06493526","Mycophenolate-Based Therapy for Kidney Transplant Recipients Without HLA-DQ Mismatch","2026-12-31","Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05893225","Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration","2027-02-28","Metformin Hydrochloride 850 mg Oral",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT04911621","Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma","2027-06-01","Dendritic cell vaccination + temozolomide-based chemoradiation",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT03464305","ASPIRIN Trial Belgium","2027-12-31","acetylsalicylic acid",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,118,151,169,187,205,231,272,294,315,360,381,404,422,444,467,485,503,531,554,577,595,636,678,705,723,749,767,785,811,829,847,872,890,915,939,964,982,1009,1027,1045,1072,1090,1108,1134,1152,1170,1188,1213,1231,1253,1281,1313,1331,1349,1367,1385,1403,1428,1446,1471,1496,1514,1536,1567,1592,1610,1635,1660,1684,1709,1733,1770,1795,1822,1847,1874,1892,1916,1943,1961,1987,2011],{"intervention":69,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":116},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":68},[107],{"nctId":66,"briefTitle":67,"status":108,"phases":109,"primaryCompletion":68,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"RECRUITING",[90],"2027-06-30","2024-08-20",20,[114],"Kidney Transplantation",[69],{"trials":117,"activeCount":98},[],{"intervention":119,"totalTrials":94,"cells":120},"Glucose 5% for fluid creep",{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":149},{"trials":122,"activeCount":98},[],{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":98},[],{"trials":130,"activeCount":94,"soonestReadout":135},[131],{"nctId":132,"briefTitle":133,"status":108,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":145},"NCT07189091","CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS",[90],"2028-04-30","2028-07-30","2025-10-07",640,[140,141,142,143,144],"Critical Care, Intensive Care","Fluid Accumulation","Fluid and Electrolyte Imbalance","Critical Illness","Fluid Balance Outcomes",[119,146,147,148],"NaCl 0.9% (normal saline) for fluid creep","PlasmaLyte as maintenance fluid","NaCl 0.3% in glucose 3.3% as maintenance fluid",{"trials":150,"activeCount":98},[],{"intervention":146,"totalTrials":94,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":167},{"trials":154,"activeCount":98},[],{"trials":156,"activeCount":98},[],{"trials":158,"activeCount":98},[],{"trials":160,"activeCount":98},[],{"trials":162,"activeCount":94,"soonestReadout":135},[163],{"nctId":132,"briefTitle":133,"status":108,"phases":164,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":165,"interventions":166},[90],[140,141,142,143,144],[119,146,147,148],{"trials":168,"activeCount":98},[],{"intervention":147,"totalTrials":94,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":185},{"trials":172,"activeCount":98},[],{"trials":174,"activeCount":98},[],{"trials":176,"activeCount":98},[],{"trials":178,"activeCount":98},[],{"trials":180,"activeCount":94,"soonestReadout":135},[181],{"nctId":132,"briefTitle":133,"status":108,"phases":182,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":183,"interventions":184},[90],[140,141,142,143,144],[119,146,147,148],{"trials":186,"activeCount":98},[],{"intervention":148,"totalTrials":94,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":203},{"trials":190,"activeCount":98},[],{"trials":192,"activeCount":98},[],{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":98},[],{"trials":198,"activeCount":94,"soonestReadout":135},[199],{"nctId":132,"briefTitle":133,"status":108,"phases":200,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":201,"interventions":202},[90],[140,141,142,143,144],[119,146,147,148],{"trials":204,"activeCount":98},[],{"intervention":206,"totalTrials":94,"cells":207},"Somatostatin analog",{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":229},{"trials":209,"activeCount":98},[],{"trials":211,"activeCount":98},[],{"trials":213,"activeCount":98},[],{"trials":215,"activeCount":98},[],{"trials":217,"activeCount":94,"soonestReadout":222},[218],{"nctId":219,"briefTitle":220,"status":108,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},"NCT05701241","Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients",[90],"2029-04","2034-04","2023-06-28",270,[227],"Gastroenteropancreatic Neuroendocrine Tumor",[206],{"trials":230,"activeCount":98},[],{"intervention":40,"totalTrials":34,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":262},{"trials":234,"activeCount":98},[],{"trials":236,"activeCount":98},[],{"trials":238,"activeCount":98},[],{"trials":240,"activeCount":98},[],{"trials":242,"activeCount":94,"soonestReadout":39},[243,254],{"nctId":244,"briefTitle":245,"status":246,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":253},"NCT04726982","Optimal Dosage of Acetazolamide for OSA Treatment","COMPLETED",[90],"2024-03-19","2024-05-05","2021-04-20",91,[15],[40,40],{"nctId":37,"briefTitle":38,"status":255,"phases":256,"primaryCompletion":39,"completion":257,"start":258,"enrollment":259,"conditions":260,"interventions":261},"ACTIVE_NOT_RECRUITING",[90],"2024-08","2020-01-22",26,[15],[40],{"trials":263,"activeCount":98},[264],{"nctId":265,"briefTitle":266,"status":267,"phases":268,"conditions":269,"interventions":270},"NCT00497120","A Combined Surgical and Medical Approach in Mild Sleep Apnea","UNKNOWN",[91],[31],[271],"acetazolamide",{"intervention":64,"totalTrials":94,"cells":273},{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":290,"NA":292},{"trials":275,"activeCount":98},[],{"trials":277,"activeCount":98},[],{"trials":279,"activeCount":98},[],{"trials":281,"activeCount":94,"soonestReadout":63},[282],{"nctId":61,"briefTitle":62,"status":108,"phases":283,"primaryCompletion":63,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":289},[89],"2028-10-01","2024-05-24",174,[288],"Acute Myocarditis",[64],{"trials":291,"activeCount":98},[],{"trials":293,"activeCount":98},[],{"intervention":84,"totalTrials":94,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":311,"NA":313},{"trials":297,"activeCount":98},[],{"trials":299,"activeCount":98},[],{"trials":301,"activeCount":98},[],{"trials":303,"activeCount":94,"soonestReadout":83},[304],{"nctId":81,"briefTitle":82,"status":255,"phases":305,"primaryCompletion":83,"completion":83,"start":306,"enrollment":307,"conditions":308,"interventions":310},[89],"2018-02-22",148,[309],"Colon Cancer",[84],{"trials":312,"activeCount":98},[],{"trials":314,"activeCount":98},[],{"intervention":316,"totalTrials":34,"cells":317},"tolerogenic dendritic cells",{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":330,"PHASE3":354,"PHASE4":356,"NA":358},{"trials":319,"activeCount":98},[],{"trials":321,"activeCount":98},[322],{"nctId":323,"briefTitle":324,"status":246,"phases":325,"primaryCompletion":326,"completion":326,"start":327,"enrollment":9,"conditions":328,"interventions":329},"NCT02618902","A \"negative\"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial",[87],"2022-02-03","2017-05-30",[24],[316],{"trials":331,"activeCount":94,"soonestReadout":347},[332,342],{"nctId":333,"briefTitle":334,"status":335,"phases":336,"primaryCompletion":337,"completion":338,"start":337,"enrollment":98,"conditions":339,"interventions":340},"NCT06715605","A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","WITHDRAWN",[88],"2025-04-30","2027-10-29",[24],[316,341],"Standard-of-care",{"nctId":343,"briefTitle":344,"status":345,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":352},"NCT07020715","A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis","NOT_YET_RECRUITING",[88],"2029-09-30","2029-10-30","2026-07-01",14,[24],[353],"Tolerogenic dendritic cells",{"trials":355,"activeCount":98},[],{"trials":357,"activeCount":98},[],{"trials":359,"activeCount":98},[],{"intervention":45,"totalTrials":94,"cells":361},{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":363,"activeCount":98},[],{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":94,"soonestReadout":44},[368],{"nctId":42,"briefTitle":43,"status":255,"phases":369,"primaryCompletion":44,"completion":370,"start":371,"enrollment":112,"conditions":372,"interventions":374},[87,88],"2025-12","2015-12",[373],"Glioblastoma Multiforme of Brain",[45],{"trials":376,"activeCount":98},[],{"trials":378,"activeCount":98},[],{"trials":380,"activeCount":98},[],{"intervention":79,"totalTrials":94,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":398,"PHASE4":400,"NA":402},{"trials":384,"activeCount":98},[],{"trials":386,"activeCount":98},[],{"trials":388,"activeCount":94,"soonestReadout":78},[389],{"nctId":76,"briefTitle":77,"status":255,"phases":390,"primaryCompletion":78,"completion":78,"start":391,"enrollment":392,"conditions":393,"interventions":396},[87,88],"2021-09-10",10,[394,395],"High Grade Glioma","Diffuse Intrinsic Pontine Glioma",[79,397],"Dendritic cell vaccination +- conventional next-line treatment",{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":98},[],{"intervention":397,"totalTrials":94,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":416,"PHASE4":418,"NA":420},{"trials":407,"activeCount":98},[],{"trials":409,"activeCount":98},[],{"trials":411,"activeCount":94,"soonestReadout":78},[412],{"nctId":76,"briefTitle":77,"status":255,"phases":413,"primaryCompletion":78,"completion":78,"start":391,"enrollment":392,"conditions":414,"interventions":415},[87,88],[394,395],[79,397],{"trials":417,"activeCount":98},[],{"trials":419,"activeCount":98},[],{"trials":421,"activeCount":98},[],{"intervention":74,"totalTrials":94,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":425,"activeCount":98},[],{"trials":427,"activeCount":98},[],{"trials":429,"activeCount":94,"soonestReadout":73},[430],{"nctId":71,"briefTitle":72,"status":255,"phases":431,"primaryCompletion":73,"completion":73,"start":432,"enrollment":433,"conditions":434,"interventions":437},[88],"2023-11-23",120,[24,435,436],"Primary Progressive Multiple Sclerosis","Secondary-progressive Multiple Sclerosis",[74],{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"intervention":59,"totalTrials":94,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":447,"activeCount":98},[],{"trials":449,"activeCount":98},[],{"trials":451,"activeCount":94,"soonestReadout":58},[452],{"nctId":56,"briefTitle":57,"status":108,"phases":453,"primaryCompletion":58,"completion":58,"start":454,"enrollment":455,"conditions":456,"interventions":458},[87,88],"2023-02-24",15,[457],"Malignant Pleural Mesothelioma",[59,459,460],"Atezolizumab","Platinum\u002Fpemetrexed based chemotherapy",{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"intervention":459,"totalTrials":94,"cells":468},{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":479,"PHASE4":481,"NA":483},{"trials":470,"activeCount":98},[],{"trials":472,"activeCount":98},[],{"trials":474,"activeCount":94,"soonestReadout":58},[475],{"nctId":56,"briefTitle":57,"status":108,"phases":476,"primaryCompletion":58,"completion":58,"start":454,"enrollment":455,"conditions":477,"interventions":478},[87,88],[457],[59,459,460],{"trials":480,"activeCount":98},[],{"trials":482,"activeCount":98},[],{"trials":484,"activeCount":98},[],{"intervention":460,"totalTrials":94,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":497,"PHASE4":499,"NA":501},{"trials":488,"activeCount":98},[],{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":94,"soonestReadout":58},[493],{"nctId":56,"briefTitle":57,"status":108,"phases":494,"primaryCompletion":58,"completion":58,"start":454,"enrollment":455,"conditions":495,"interventions":496},[87,88],[457],[59,459,460],{"trials":498,"activeCount":98},[],{"trials":500,"activeCount":98},[],{"trials":502,"activeCount":98},[],{"intervention":504,"totalTrials":94,"cells":505},"Neoadjuvant chemo-immunotherapy",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":507,"activeCount":98},[],{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":94,"soonestReadout":516},[512],{"nctId":513,"briefTitle":514,"status":108,"phases":515,"primaryCompletion":516,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":524},"NCT07121374","NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study",[87,88],"2028-06","2029-07","2025-07-22",37,[521,522,523],"Pleural Epithelioid Mesothelioma","Mesothelioma; Pleura","Neoadjuvant Chemoimmunotherapy",[504],{"trials":526,"activeCount":98},[],{"trials":528,"activeCount":98},[],{"trials":530,"activeCount":98},[],{"intervention":54,"totalTrials":94,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":534,"activeCount":98},[],{"trials":536,"activeCount":98},[],{"trials":538,"activeCount":94,"soonestReadout":53},[539],{"nctId":51,"briefTitle":52,"status":255,"phases":540,"primaryCompletion":53,"completion":53,"start":541,"enrollment":392,"conditions":542,"interventions":547},[87,88],"2023-12-06",[543,544,545,546],"Esophageal Cancer","Pancreas Cancer","Ovarian Cancer","Liver Cancer",[54],{"trials":549,"activeCount":98},[],{"trials":551,"activeCount":98},[],{"trials":553,"activeCount":98},[],{"intervention":49,"totalTrials":94,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":569,"PHASE3":571,"PHASE4":573,"NA":575},{"trials":557,"activeCount":98},[],{"trials":559,"activeCount":94,"soonestReadout":44},[560],{"nctId":47,"briefTitle":48,"status":108,"phases":561,"primaryCompletion":44,"completion":562,"start":563,"enrollment":392,"conditions":564,"interventions":567},[87],"2026-12","2022-07-15",[565,566],"Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory",[49,568],"6-mercaptopurine",{"trials":570,"activeCount":98},[],{"trials":572,"activeCount":98},[],{"trials":574,"activeCount":98},[],{"trials":576,"activeCount":98},[],{"intervention":568,"totalTrials":94,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":587,"PHASE3":589,"PHASE4":591,"NA":593},{"trials":580,"activeCount":98},[],{"trials":582,"activeCount":94,"soonestReadout":44},[583],{"nctId":47,"briefTitle":48,"status":108,"phases":584,"primaryCompletion":44,"completion":562,"start":563,"enrollment":392,"conditions":585,"interventions":586},[87],[565,566],[49,568],{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":98},[],{"trials":592,"activeCount":98},[],{"trials":594,"activeCount":98},[],{"intervention":596,"totalTrials":597,"cells":598},"Levobupivacaine",2,{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":607,"NA":634},{"trials":600,"activeCount":98},[],{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":98},[],{"trials":606,"activeCount":98},[],{"trials":608,"activeCount":98},[609,621],{"nctId":610,"briefTitle":611,"status":246,"phases":612,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":617,"interventions":619},"NCT02879916","Comparison of an Interscalene Nerve Block With or Without Stellate Ganglion Block for Shoulder Surgery",[90],"2013-12","2016-09","2011-10",30,[618],"Anesthesia, Regional",[596,620],"NaCl 0.9%",{"nctId":622,"briefTitle":623,"status":624,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":632},"NCT03456661","Comparison Between Levobupivacaine and Levobupivacaine With Dexmedetomidine in Ultrasound Guided Pectoral Nerve Block","TERMINATED",[90],"2018-01-12","2014-05-19",40,[630,631],"Breast Cancer","Mastectomy, Modified Radical",[596,633],"Levobupivacaine + Dexmedetomidine",{"trials":635,"activeCount":98},[],{"intervention":637,"totalTrials":597,"cells":638},"cyclosporine",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":647,"NA":676},{"trials":640,"activeCount":98},[],{"trials":642,"activeCount":98},[],{"trials":644,"activeCount":98},[],{"trials":646,"activeCount":98},[],{"trials":648,"activeCount":98},[649,661],{"nctId":650,"briefTitle":651,"status":267,"phases":652,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":659},"NCT00903188","Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation",[90],"2010-04","2015-04","2008-10",152,[658],"Renal Transplantation",[637,660],"Everolimus",{"nctId":662,"briefTitle":663,"status":267,"phases":664,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":673},"NCT00493194","Fibrosis in Renal Allografts",[90],"2007-07","2005-05",100,[669,670,671,672],"Kidney Failure, Chronic","Transplantation","Immunosuppression","Interstitial Fibrosis",[674,637,675],"sirolimus","daclizumab",{"trials":677,"activeCount":98},[],{"intervention":679,"totalTrials":94,"cells":680},"Salbutamol",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":689,"NA":703},{"trials":682,"activeCount":98},[],{"trials":684,"activeCount":98},[],{"trials":686,"activeCount":98},[],{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":98},[691],{"nctId":692,"briefTitle":693,"status":246,"phases":694,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT00911651","Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients",[90],"2008-07","2008-08","2008-06",6,[700],"COPD",[679,702],"ipratropium bromide",{"trials":704,"activeCount":98},[],{"intervention":702,"totalTrials":94,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":715,"NA":721},{"trials":708,"activeCount":98},[],{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":98},[],{"trials":716,"activeCount":98},[717],{"nctId":692,"briefTitle":693,"status":246,"phases":718,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":719,"interventions":720},[90],[700],[679,702],{"trials":722,"activeCount":98},[],{"intervention":724,"totalTrials":94,"cells":725},"continuous infusion of levobupivacaine",{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":732,"PHASE4":734,"NA":747},{"trials":727,"activeCount":98},[],{"trials":729,"activeCount":98},[],{"trials":731,"activeCount":98},[],{"trials":733,"activeCount":98},[],{"trials":735,"activeCount":98},[736],{"nctId":737,"briefTitle":738,"status":246,"phases":739,"primaryCompletion":740,"completion":740,"start":741,"enrollment":742,"conditions":743,"interventions":745},"NCT02293330","Continuous Versus Automated Bolus Infusion in Sciatic Nerve Catheters",[90],"2016-11","2014-11",71,[744,21],"Hallux Valgus",[724,746],"Intermittent bolus infusion of levobupivacaine",{"trials":748,"activeCount":98},[],{"intervention":746,"totalTrials":94,"cells":750},{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":765},{"trials":752,"activeCount":98},[],{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":98},[761],{"nctId":737,"briefTitle":738,"status":246,"phases":762,"primaryCompletion":740,"completion":740,"start":741,"enrollment":742,"conditions":763,"interventions":764},[90],[744,21],[724,746],{"trials":766,"activeCount":98},[],{"intervention":620,"totalTrials":94,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":783},{"trials":770,"activeCount":98},[],{"trials":772,"activeCount":98},[],{"trials":774,"activeCount":98},[],{"trials":776,"activeCount":98},[],{"trials":778,"activeCount":98},[779],{"nctId":610,"briefTitle":611,"status":246,"phases":780,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":781,"interventions":782},[90],[618],[596,620],{"trials":784,"activeCount":98},[],{"intervention":786,"totalTrials":94,"cells":787},"Ropivacaine 0.75%",{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":809},{"trials":789,"activeCount":98},[],{"trials":791,"activeCount":98},[],{"trials":793,"activeCount":98},[],{"trials":795,"activeCount":98},[],{"trials":797,"activeCount":98},[798],{"nctId":799,"briefTitle":800,"status":246,"phases":801,"primaryCompletion":371,"completion":802,"start":803,"enrollment":616,"conditions":804,"interventions":806},"NCT02691442","Comparison of the Analgesic Effect of Different Local Anesthetics in Interscalene Nerve Block for Shoulder Surgery",[90],"2016-04","2010-12",[805],"Other Peripheral Nerve Disease",[786,807,808],"Levobupivacaine 0.5%","Levobupivacaine 0.5% + epinephrin 1\u002F200000",{"trials":810,"activeCount":98},[],{"intervention":807,"totalTrials":94,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":821,"NA":827},{"trials":814,"activeCount":98},[],{"trials":816,"activeCount":98},[],{"trials":818,"activeCount":98},[],{"trials":820,"activeCount":98},[],{"trials":822,"activeCount":98},[823],{"nctId":799,"briefTitle":800,"status":246,"phases":824,"primaryCompletion":371,"completion":802,"start":803,"enrollment":616,"conditions":825,"interventions":826},[90],[805],[786,807,808],{"trials":828,"activeCount":98},[],{"intervention":808,"totalTrials":94,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":839,"NA":845},{"trials":832,"activeCount":98},[],{"trials":834,"activeCount":98},[],{"trials":836,"activeCount":98},[],{"trials":838,"activeCount":98},[],{"trials":840,"activeCount":98},[841],{"nctId":799,"briefTitle":800,"status":246,"phases":842,"primaryCompletion":371,"completion":802,"start":803,"enrollment":616,"conditions":843,"interventions":844},[90],[805],[786,807,808],{"trials":846,"activeCount":98},[],{"intervention":848,"totalTrials":94,"cells":849},"Alfarix",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":870},{"trials":851,"activeCount":98},[],{"trials":853,"activeCount":98},[],{"trials":855,"activeCount":98},[],{"trials":857,"activeCount":98},[],{"trials":859,"activeCount":98},[860],{"nctId":861,"briefTitle":862,"status":246,"phases":863,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":869},"NCT00221676","Effectiveness of Influenza Vaccination Among General Practitioners",[90],"2004-06","2002-07",300,[868],"Influenza",[848],{"trials":871,"activeCount":98},[],{"intervention":660,"totalTrials":94,"cells":873},{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":880,"PHASE4":882,"NA":888},{"trials":875,"activeCount":98},[],{"trials":877,"activeCount":98},[],{"trials":879,"activeCount":98},[],{"trials":881,"activeCount":98},[],{"trials":883,"activeCount":98},[884],{"nctId":650,"briefTitle":651,"status":267,"phases":885,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":886,"interventions":887},[90],[658],[637,660],{"trials":889,"activeCount":98},[],{"intervention":891,"totalTrials":94,"cells":892},"Orkambi",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":901,"NA":913},{"trials":894,"activeCount":98},[],{"trials":896,"activeCount":98},[],{"trials":898,"activeCount":98},[],{"trials":900,"activeCount":98},[],{"trials":902,"activeCount":98},[903],{"nctId":904,"briefTitle":905,"status":624,"phases":906,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":912},"NCT03956589","Functional Respiratory Imaging and Orkambi in CF",[90],"2020-04-01","2018-10-01",12,[911],"Cystic Fibrosis",[891],{"trials":914,"activeCount":98},[],{"intervention":916,"totalTrials":94,"cells":917},"Symbicort® forte Turbohaler®",{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":922,"PHASE3":924,"PHASE4":926,"NA":937},{"trials":919,"activeCount":98},[],{"trials":921,"activeCount":98},[],{"trials":923,"activeCount":98},[],{"trials":925,"activeCount":98},[],{"trials":927,"activeCount":98},[928],{"nctId":929,"briefTitle":930,"status":246,"phases":931,"primaryCompletion":932,"completion":933,"start":934,"enrollment":392,"conditions":935,"interventions":936},"NCT01329276","Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.",[90],"2010-11","2011-01","2010-06",[26],[916],{"trials":938,"activeCount":98},[],{"intervention":940,"totalTrials":94,"cells":941},"Deanxit",{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":948,"PHASE4":950,"NA":962},{"trials":943,"activeCount":98},[],{"trials":945,"activeCount":98},[],{"trials":947,"activeCount":98},[],{"trials":949,"activeCount":98},[],{"trials":951,"activeCount":98},[952],{"nctId":953,"briefTitle":954,"status":246,"phases":955,"primaryCompletion":956,"completion":956,"start":957,"enrollment":958,"conditions":959,"interventions":960},"NCT00841230","Deanxit and Rivotril in Tinnitus Patients",[90],"2009-07","2009-02",50,[18],[940,961],"Lactose placebo",{"trials":963,"activeCount":98},[],{"intervention":961,"totalTrials":94,"cells":965},{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":972,"PHASE4":974,"NA":980},{"trials":967,"activeCount":98},[],{"trials":969,"activeCount":98},[],{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":98},[],{"trials":975,"activeCount":98},[976],{"nctId":953,"briefTitle":954,"status":246,"phases":977,"primaryCompletion":956,"completion":956,"start":957,"enrollment":958,"conditions":978,"interventions":979},[90],[18],[940,961],{"trials":981,"activeCount":98},[],{"intervention":983,"totalTrials":94,"cells":984},"Lidocaine patch 5%",{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":991,"PHASE4":993,"NA":1007},{"trials":986,"activeCount":98},[],{"trials":988,"activeCount":98},[],{"trials":990,"activeCount":98},[],{"trials":992,"activeCount":98},[],{"trials":994,"activeCount":98},[995],{"nctId":996,"briefTitle":997,"status":624,"phases":998,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1004},"NCT03348735","Localized Neuropathic Pain: Topical Treatment Versus Systemic Treatment",[90],"2021-04-19","2018-12-03",33,[1003],"Neuropathic Pain",[983,1005,1006],"Capsaicin 8% Patch","Pregabalin",{"trials":1008,"activeCount":98},[],{"intervention":1005,"totalTrials":94,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1017,"PHASE4":1019,"NA":1025},{"trials":1012,"activeCount":98},[],{"trials":1014,"activeCount":98},[],{"trials":1016,"activeCount":98},[],{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[1021],{"nctId":996,"briefTitle":997,"status":624,"phases":1022,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1023,"interventions":1024},[90],[1003],[983,1005,1006],{"trials":1026,"activeCount":98},[],{"intervention":1006,"totalTrials":94,"cells":1028},{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1043},{"trials":1030,"activeCount":98},[],{"trials":1032,"activeCount":98},[],{"trials":1034,"activeCount":98},[],{"trials":1036,"activeCount":98},[],{"trials":1038,"activeCount":98},[1039],{"nctId":996,"briefTitle":997,"status":624,"phases":1040,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1041,"interventions":1042},[90],[1003],[983,1005,1006],{"trials":1044,"activeCount":98},[],{"intervention":1046,"totalTrials":94,"cells":1047},"Unfractionated heparin",{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1056,"NA":1070},{"trials":1049,"activeCount":98},[],{"trials":1051,"activeCount":98},[],{"trials":1053,"activeCount":98},[],{"trials":1055,"activeCount":98},[],{"trials":1057,"activeCount":98},[1058],{"nctId":1059,"briefTitle":1060,"status":267,"phases":1061,"primaryCompletion":1062,"completion":1063,"start":933,"enrollment":1064,"conditions":1065,"interventions":1068},"NCT01228292","Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.",[90],"2012-01","2013-01",250,[1066,1067],"Acute Kidney Injury","Hemodialysis",[1046,1069],"Citrasate",{"trials":1071,"activeCount":98},[],{"intervention":1069,"totalTrials":94,"cells":1073},{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1080,"PHASE4":1082,"NA":1088},{"trials":1075,"activeCount":98},[],{"trials":1077,"activeCount":98},[],{"trials":1079,"activeCount":98},[],{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":98},[1084],{"nctId":1059,"briefTitle":1060,"status":267,"phases":1085,"primaryCompletion":1062,"completion":1063,"start":933,"enrollment":1064,"conditions":1086,"interventions":1087},[90],[1066,1067],[1046,1069],{"trials":1089,"activeCount":98},[],{"intervention":633,"totalTrials":94,"cells":1091},{"EARLY_PHASE1":1092,"PHASE1":1094,"PHASE2":1096,"PHASE3":1098,"PHASE4":1100,"NA":1106},{"trials":1093,"activeCount":98},[],{"trials":1095,"activeCount":98},[],{"trials":1097,"activeCount":98},[],{"trials":1099,"activeCount":98},[],{"trials":1101,"activeCount":98},[1102],{"nctId":622,"briefTitle":623,"status":624,"phases":1103,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":1104,"interventions":1105},[90],[630,631],[596,633],{"trials":1107,"activeCount":98},[],{"intervention":1109,"totalTrials":94,"cells":1110},"spinal dexmedetomidine 0.5 mcg",{"EARLY_PHASE1":1111,"PHASE1":1113,"PHASE2":1115,"PHASE3":1117,"PHASE4":1119,"NA":1132},{"trials":1112,"activeCount":98},[],{"trials":1114,"activeCount":98},[],{"trials":1116,"activeCount":98},[],{"trials":1118,"activeCount":98},[],{"trials":1120,"activeCount":98},[1121],{"nctId":1122,"briefTitle":1123,"status":246,"phases":1124,"primaryCompletion":1125,"completion":1125,"start":1126,"enrollment":1127,"conditions":1128,"interventions":1130},"NCT02282319","Spinal or Intravenous Dexmedetomidine in Ambulatory Surgery",[90],"2020-12","2014-10",150,[1129],"Surgery Ambulatory",[1109,1131],"IV dexmedetomidine 0.5 mcg\u002Fkg",{"trials":1133,"activeCount":98},[],{"intervention":1131,"totalTrials":94,"cells":1135},{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1142,"PHASE4":1144,"NA":1150},{"trials":1137,"activeCount":98},[],{"trials":1139,"activeCount":98},[],{"trials":1141,"activeCount":98},[],{"trials":1143,"activeCount":98},[],{"trials":1145,"activeCount":98},[1146],{"nctId":1122,"briefTitle":1123,"status":246,"phases":1147,"primaryCompletion":1125,"completion":1125,"start":1126,"enrollment":1127,"conditions":1148,"interventions":1149},[90],[1129],[1109,1131],{"trials":1151,"activeCount":98},[],{"intervention":674,"totalTrials":94,"cells":1153},{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1160,"PHASE4":1162,"NA":1168},{"trials":1155,"activeCount":98},[],{"trials":1157,"activeCount":98},[],{"trials":1159,"activeCount":98},[],{"trials":1161,"activeCount":98},[],{"trials":1163,"activeCount":98},[1164],{"nctId":662,"briefTitle":663,"status":267,"phases":1165,"completion":665,"start":666,"enrollment":667,"conditions":1166,"interventions":1167},[90],[669,670,671,672],[674,637,675],{"trials":1169,"activeCount":98},[],{"intervention":675,"totalTrials":94,"cells":1171},{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1178,"PHASE4":1180,"NA":1186},{"trials":1173,"activeCount":98},[],{"trials":1175,"activeCount":98},[],{"trials":1177,"activeCount":98},[],{"trials":1179,"activeCount":98},[],{"trials":1181,"activeCount":98},[1182],{"nctId":662,"briefTitle":663,"status":267,"phases":1183,"completion":665,"start":666,"enrollment":667,"conditions":1184,"interventions":1185},[90],[669,670,671,672],[674,637,675],{"trials":1187,"activeCount":98},[],{"intervention":1189,"totalTrials":94,"cells":1190},"NaCl 0.9% in Glucose 5% with 40mEq Potassium",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1197,"PHASE4":1199,"NA":1211},{"trials":1192,"activeCount":98},[],{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":98},[],{"trials":1198,"activeCount":98},[],{"trials":1200,"activeCount":98},[1201],{"nctId":1202,"briefTitle":1203,"status":246,"phases":1204,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":909,"conditions":1207,"interventions":1209},"NCT02822898","Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults",[90],"2016-08","2016-06",[1208],"Healthy Adult Volunteers",[1189,1210],"Glucion 5%",{"trials":1212,"activeCount":98},[],{"intervention":1210,"totalTrials":94,"cells":1214},{"EARLY_PHASE1":1215,"PHASE1":1217,"PHASE2":1219,"PHASE3":1221,"PHASE4":1223,"NA":1229},{"trials":1216,"activeCount":98},[],{"trials":1218,"activeCount":98},[],{"trials":1220,"activeCount":98},[],{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[1225],{"nctId":1202,"briefTitle":1203,"status":246,"phases":1226,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":909,"conditions":1227,"interventions":1228},[90],[1208],[1189,1210],{"trials":1230,"activeCount":98},[],{"intervention":1232,"totalTrials":94,"cells":1233},"N-acetylcysteine",{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1240,"PHASE4":1242,"NA":1251},{"trials":1235,"activeCount":98},[],{"trials":1237,"activeCount":98},[],{"trials":1239,"activeCount":98},[],{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[1244],{"nctId":1245,"briefTitle":1246,"status":246,"phases":1247,"primaryCompletion":933,"completion":933,"start":1248,"enrollment":909,"conditions":1249,"interventions":1250},"NCT00969904","Pilot Study to Assess the Effect of High Dose N-acetylcysteine (NAC) in Chronic Obstructive Pulmonary Disease (COPD) Patients",[90],"2009-03",[700],[1232],{"trials":1252,"activeCount":98},[],{"intervention":1254,"totalTrials":94,"cells":1255},"Norepinephrine",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1279},{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[],{"trials":1261,"activeCount":98},[],{"trials":1263,"activeCount":98},[],{"trials":1265,"activeCount":98},[1266],{"nctId":1267,"briefTitle":1268,"status":624,"phases":1269,"primaryCompletion":1270,"completion":1271,"start":1272,"enrollment":1273,"conditions":1274,"interventions":1278},"NCT05264870","Norepinephrine in Caesarian Section",[90],"2023-03-02","2025-08-27","2022-06-09",11,[1275,1276,1277],"Cesarean Section Complications","Hemodynamic Instability","Foetal Stress",[1254,1254],{"trials":1280,"activeCount":98},[],{"intervention":1282,"totalTrials":94,"cells":1283},"sugammadex 2mg\u002Fkg",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1290,"PHASE4":1309,"NA":1311},{"trials":1285,"activeCount":98},[],{"trials":1287,"activeCount":98},[],{"trials":1289,"activeCount":98},[],{"trials":1291,"activeCount":98},[1292],{"nctId":1293,"briefTitle":1294,"status":246,"phases":1295,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1303},"NCT01962298","Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex",[89],"2014-12","2013-10",75,[1300,1301,1302],"Diaphragmatic Dysfunction","Muscle Weakness","Muscle Fatigue",[1282,1304,1305,1306,1307,1308],"neostigmine","sugammadex 4mg\u002Fkg","Single rocuronium dose","Repeated rocuronium dose","Continuous rocuronium",{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[],{"intervention":1304,"totalTrials":94,"cells":1314},{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1321,"PHASE4":1327,"NA":1329},{"trials":1316,"activeCount":98},[],{"trials":1318,"activeCount":98},[],{"trials":1320,"activeCount":98},[],{"trials":1322,"activeCount":98},[1323],{"nctId":1293,"briefTitle":1294,"status":246,"phases":1324,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":1298,"conditions":1325,"interventions":1326},[89],[1300,1301,1302],[1282,1304,1305,1306,1307,1308],{"trials":1328,"activeCount":98},[],{"trials":1330,"activeCount":98},[],{"intervention":1305,"totalTrials":94,"cells":1332},{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1337,"PHASE3":1339,"PHASE4":1345,"NA":1347},{"trials":1334,"activeCount":98},[],{"trials":1336,"activeCount":98},[],{"trials":1338,"activeCount":98},[],{"trials":1340,"activeCount":98},[1341],{"nctId":1293,"briefTitle":1294,"status":246,"phases":1342,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":1298,"conditions":1343,"interventions":1344},[89],[1300,1301,1302],[1282,1304,1305,1306,1307,1308],{"trials":1346,"activeCount":98},[],{"trials":1348,"activeCount":98},[],{"intervention":1306,"totalTrials":94,"cells":1350},{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1357,"PHASE4":1363,"NA":1365},{"trials":1352,"activeCount":98},[],{"trials":1354,"activeCount":98},[],{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[1359],{"nctId":1293,"briefTitle":1294,"status":246,"phases":1360,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":1298,"conditions":1361,"interventions":1362},[89],[1300,1301,1302],[1282,1304,1305,1306,1307,1308],{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":98},[],{"intervention":1307,"totalTrials":94,"cells":1368},{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1381,"NA":1383},{"trials":1370,"activeCount":98},[],{"trials":1372,"activeCount":98},[],{"trials":1374,"activeCount":98},[],{"trials":1376,"activeCount":98},[1377],{"nctId":1293,"briefTitle":1294,"status":246,"phases":1378,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":1298,"conditions":1379,"interventions":1380},[89],[1300,1301,1302],[1282,1304,1305,1306,1307,1308],{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[],{"intervention":1308,"totalTrials":94,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1399,"NA":1401},{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[],{"trials":1394,"activeCount":98},[1395],{"nctId":1293,"briefTitle":1294,"status":246,"phases":1396,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":1298,"conditions":1397,"interventions":1398},[89],[1300,1301,1302],[1282,1304,1305,1306,1307,1308],{"trials":1400,"activeCount":98},[],{"trials":1402,"activeCount":98},[],{"intervention":1404,"totalTrials":94,"cells":1405},"cisplatin + docetaxel",{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1424,"NA":1426},{"trials":1407,"activeCount":98},[],{"trials":1409,"activeCount":98},[],{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[1414],{"nctId":1415,"briefTitle":1416,"status":246,"phases":1417,"primaryCompletion":1418,"completion":1418,"start":697,"enrollment":1419,"conditions":1420,"interventions":1422},"NCT00771563","Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)",[89],"2012-10",104,[1421],"Non-Small Cell Lung Cancer",[1404,1423],"cisplatin + docetaxel + enoxaparin",{"trials":1425,"activeCount":98},[],{"trials":1427,"activeCount":98},[],{"intervention":1423,"totalTrials":94,"cells":1429},{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1442,"NA":1444},{"trials":1431,"activeCount":98},[],{"trials":1433,"activeCount":98},[],{"trials":1435,"activeCount":98},[],{"trials":1437,"activeCount":98},[1438],{"nctId":1415,"briefTitle":1416,"status":246,"phases":1439,"primaryCompletion":1418,"completion":1418,"start":697,"enrollment":1419,"conditions":1440,"interventions":1441},[89],[1421],[1404,1423],{"trials":1443,"activeCount":98},[],{"trials":1445,"activeCount":98},[],{"intervention":1447,"totalTrials":94,"cells":1448},"Inuvair",{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1455,"PHASE4":1467,"NA":1469},{"trials":1450,"activeCount":98},[],{"trials":1452,"activeCount":98},[],{"trials":1454,"activeCount":98},[],{"trials":1456,"activeCount":98},[1457],{"nctId":1458,"briefTitle":1459,"status":246,"phases":1460,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":1464,"conditions":1465,"interventions":1466},"NCT01204034","Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[89],"2012-03","2012-06","2010-09",29,[26],[1447],{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":98},[],{"intervention":1472,"totalTrials":94,"cells":1473},"Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg",{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1475,"activeCount":98},[],{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[1480],{"nctId":1481,"briefTitle":1482,"status":246,"phases":1483,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":1486,"conditions":1487,"interventions":1489},"NCT01650441","Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients",[88],"2013-06","2012-04",31,[1488],"Asthma",[1472],{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":98},[],{"trials":1495,"activeCount":98},[],{"intervention":341,"totalTrials":94,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1499,"activeCount":98},[],{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":98},[1504],{"nctId":333,"briefTitle":334,"status":335,"phases":1505,"primaryCompletion":337,"completion":338,"start":337,"enrollment":98,"conditions":1506,"interventions":1507},[88],[24],[316,341],{"trials":1509,"activeCount":98},[],{"trials":1511,"activeCount":98},[],{"trials":1513,"activeCount":98},[],{"intervention":1515,"totalTrials":94,"cells":1516},"combination chemotherapy",{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1530,"PHASE4":1532,"NA":1534},{"trials":1518,"activeCount":98},[],{"trials":1520,"activeCount":98},[],{"trials":1522,"activeCount":98},[1523],{"nctId":1524,"briefTitle":1525,"status":246,"phases":1526,"primaryCompletion":1248,"completion":1248,"start":1527,"enrollment":616,"conditions":1528,"interventions":1529},"NCT00497315","Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)",[88],"2006-02",[1421],[1515],{"trials":1531,"activeCount":98},[],{"trials":1533,"activeCount":98},[],{"trials":1535,"activeCount":98},[],{"intervention":1537,"totalTrials":94,"cells":1538},"autologous dendritic cell vaccination",{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1561,"PHASE4":1563,"NA":1565},{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":98},[],{"trials":1544,"activeCount":98},[1545],{"nctId":1546,"briefTitle":1547,"status":246,"phases":1548,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":1552,"conditions":1553,"interventions":1560},"NCT01291420","Dendritic Cell Vaccination for Patients with Solid Tumors",[87,88],"2016-04-25","2017-11-02","2010-05-03",48,[1554,1555,1556,1557,1558,1559],"Glioblastoma","Renal Cell Carcinoma","Sarcomas","Breast Cancers","Malignant Mesothelioma","Colorectal Tumors",[1537],{"trials":1562,"activeCount":98},[],{"trials":1564,"activeCount":98},[],{"trials":1566,"activeCount":98},[],{"intervention":1568,"totalTrials":94,"cells":1569},"cisplatin\u002Fdocetaxel",{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1586,"PHASE4":1588,"NA":1590},{"trials":1571,"activeCount":98},[],{"trials":1573,"activeCount":98},[],{"trials":1575,"activeCount":98},[1576],{"nctId":1577,"briefTitle":1578,"status":246,"phases":1579,"primaryCompletion":1463,"completion":932,"start":1580,"enrollment":1581,"conditions":1582,"interventions":1584},"NCT00434668","Evaluation of Tolerability of Adjuvant Cisplatin\u002FDocetaxel in Completely Resected Stage IB\u002FII Non-Small Cell Lung Cancer",[88],"2005-12",99,[1583],"Non-small Cell Lung Cancer",[1568,1585],"cisplatin\u002Fvinorelbine",{"trials":1587,"activeCount":98},[],{"trials":1589,"activeCount":98},[],{"trials":1591,"activeCount":98},[],{"intervention":1585,"totalTrials":94,"cells":1593},{"EARLY_PHASE1":1594,"PHASE1":1596,"PHASE2":1598,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1595,"activeCount":98},[],{"trials":1597,"activeCount":98},[],{"trials":1599,"activeCount":98},[1600],{"nctId":1577,"briefTitle":1578,"status":246,"phases":1601,"primaryCompletion":1463,"completion":932,"start":1580,"enrollment":1581,"conditions":1602,"interventions":1603},[88],[1583],[1568,1585],{"trials":1605,"activeCount":98},[],{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":98},[],{"intervention":1611,"totalTrials":94,"cells":1612},"Limbal epithelial stem cell graft",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1614,"activeCount":98},[],{"trials":1616,"activeCount":98},[],{"trials":1618,"activeCount":98},[1619],{"nctId":1620,"briefTitle":1621,"status":246,"phases":1622,"primaryCompletion":1623,"completion":1624,"start":654,"enrollment":1625,"conditions":1626,"interventions":1628},"NCT02318485","Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial",[88],"2023-01","2024-04-22",27,[1627],"Limbal Stem Cell Deficiency",[1611],{"trials":1630,"activeCount":98},[],{"trials":1632,"activeCount":98},[],{"trials":1634,"activeCount":98},[],{"intervention":1636,"totalTrials":94,"cells":1637},"carboplatin\u002Fgemcitabine",{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1642,"PHASE3":1654,"PHASE4":1656,"NA":1658},{"trials":1639,"activeCount":98},[],{"trials":1641,"activeCount":98},[],{"trials":1643,"activeCount":98},[1644],{"nctId":1645,"briefTitle":1646,"status":246,"phases":1647,"primaryCompletion":1648,"completion":1648,"start":1649,"enrollment":1650,"conditions":1651,"interventions":1653},"NCT00463515","Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC",[88],"2006-11","2003-01",77,[1652],"Non-Small-Cell-Lung Cancer",[1636],{"trials":1655,"activeCount":98},[],{"trials":1657,"activeCount":98},[],{"trials":1659,"activeCount":98},[],{"intervention":1661,"totalTrials":94,"cells":1662},"dendritic cell vaccination plus chemotherapy",{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1678,"PHASE4":1680,"NA":1682},{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[],{"trials":1668,"activeCount":98},[1669],{"nctId":1670,"briefTitle":1671,"status":246,"phases":1672,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":1675,"conditions":1676,"interventions":1677},"NCT02649829","Autologous Dendritic Cell Vaccination in Mesothelioma",[87,88],"2025-03-09","2017-10-03",28,[457],[1661],{"trials":1679,"activeCount":98},[],{"trials":1681,"activeCount":98},[],{"trials":1683,"activeCount":98},[],{"intervention":1685,"totalTrials":94,"cells":1686},"injection of antigen-loaded cultured dendritic cells",{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1701,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1688,"activeCount":98},[],{"trials":1690,"activeCount":98},[1691],{"nctId":1692,"briefTitle":1693,"status":246,"phases":1694,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":392,"conditions":1698,"interventions":1700},"NCT00834002","Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission",[87],"2007-11","2008-12","2005-03",[1699],"Acute Myeloid Leukemia (AML)",[1685],{"trials":1702,"activeCount":98},[],{"trials":1704,"activeCount":98},[],{"trials":1706,"activeCount":98},[],{"trials":1708,"activeCount":98},[],{"intervention":1710,"totalTrials":94,"cells":1711},"99mTc-Duramycin",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1725,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":98},[1716],{"nctId":1717,"briefTitle":1718,"status":246,"phases":1719,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":698,"conditions":1722,"interventions":1724},"NCT05177640","Biodistribution and Dosimetry of 99mTc-Duramycin",[87],"2021-12-14","2021-06-17",[1723],"Healthy Volunteers",[1710],{"trials":1726,"activeCount":98},[],{"trials":1728,"activeCount":98},[],{"trials":1730,"activeCount":98},[],{"trials":1732,"activeCount":98},[],{"intervention":1734,"totalTrials":597,"cells":1735},"Ropivacaine",{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1737,"activeCount":98},[],{"trials":1739,"activeCount":98},[],{"trials":1741,"activeCount":98},[],{"trials":1743,"activeCount":98},[],{"trials":1745,"activeCount":98},[],{"trials":1747,"activeCount":98},[1748,1758],{"nctId":1749,"briefTitle":1750,"status":246,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":455,"conditions":1754,"interventions":1757},"NCT03214536","Erector Spine Block for Back Surgery",[91],"2017-10-30","2017-06-25",[1755,1756],"Spine Disease","Regional Anaesthesia",[1734],{"nctId":1759,"briefTitle":1760,"status":246,"phases":1761,"primaryCompletion":1762,"completion":1763,"start":1764,"enrollment":628,"conditions":1765,"interventions":1769},"NCT04996290","Combined PENG and LFCN Block for Total Hip Arthroplasty",[91],"2020-09-30","2020-10-01","2020-06-01",[1766,1767,1768],"Anesthesia, Conduction","Pain, Postoperative","Arthroplasty, Replacement, Hip",[1734],{"intervention":1771,"totalTrials":94,"cells":1772},"Onivyde® + 5-FULV",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1783},{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[],{"trials":1778,"activeCount":98},[],{"trials":1780,"activeCount":98},[],{"trials":1782,"activeCount":98},[],{"trials":1784,"activeCount":98},[1785],{"nctId":1786,"briefTitle":1787,"status":267,"phases":1788,"primaryCompletion":1789,"completion":1789,"start":1790,"enrollment":1791,"conditions":1792,"interventions":1794},"NCT05095064","Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan",[],"2022-03-01","2021-09-27",60,[1793],"Metastatic Pancreatic Ductal Adenocarcinoma",[1771],{"intervention":1796,"totalTrials":94,"cells":1797},"Scandicaine",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1808},{"trials":1799,"activeCount":98},[],{"trials":1801,"activeCount":98},[],{"trials":1803,"activeCount":98},[],{"trials":1805,"activeCount":98},[],{"trials":1807,"activeCount":98},[],{"trials":1809,"activeCount":98},[1810],{"nctId":1811,"briefTitle":1812,"status":246,"phases":1813,"primaryCompletion":1814,"completion":1815,"start":1816,"enrollment":1127,"conditions":1817,"interventions":1821},"NCT03211949","Ultrasound Guided Topographic Mapping of Medial Antebrachial Cutaneous Nerve",[91],"2019-12","2020-01-30","2014-09",[1818,21,1819,1820],"Nerve Block","Anesthesia","Brachial Plexus Block",[1796],{"intervention":1823,"totalTrials":94,"cells":1824},"Probiotic chewables",{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1829,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1826,"activeCount":98},[],{"trials":1828,"activeCount":98},[],{"trials":1830,"activeCount":98},[],{"trials":1832,"activeCount":98},[],{"trials":1834,"activeCount":98},[],{"trials":1836,"activeCount":98},[1837],{"nctId":1838,"briefTitle":1839,"status":246,"phases":1840,"primaryCompletion":1841,"completion":1841,"start":1842,"enrollment":1843,"conditions":1844,"interventions":1846},"NCT04898686","Probiotic Chewables in Allergic Rhinoconjunctivitis Patients",[91],"2021-08-06","2020-08-01",64,[1845],"Allergic Rhinoconjunctivitis",[1823],{"intervention":1848,"totalTrials":94,"cells":1849},"Saliva collection",{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1851,"activeCount":98},[],{"trials":1853,"activeCount":98},[],{"trials":1855,"activeCount":98},[],{"trials":1857,"activeCount":98},[],{"trials":1859,"activeCount":98},[],{"trials":1861,"activeCount":98},[1862],{"nctId":1863,"briefTitle":1864,"status":267,"phases":1865,"primaryCompletion":1866,"completion":1866,"start":1867,"enrollment":1868,"conditions":1869,"interventions":1872},"NCT06257004","Genome-wide Epistasis for Cardiovascular Severity in Marfan Study",[],"2025-10-31","2020-11-30",200,[1870,1871],"Marfan Syndrome","FBN1 Mutation",[1848,1873],"Bloodsampling",{"intervention":1873,"totalTrials":94,"cells":1875},{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1880,"PHASE3":1882,"PHASE4":1884,"NA":1886},{"trials":1877,"activeCount":98},[],{"trials":1879,"activeCount":98},[],{"trials":1881,"activeCount":98},[],{"trials":1883,"activeCount":98},[],{"trials":1885,"activeCount":98},[],{"trials":1887,"activeCount":98},[1888],{"nctId":1863,"briefTitle":1864,"status":267,"phases":1889,"primaryCompletion":1866,"completion":1866,"start":1867,"enrollment":1868,"conditions":1890,"interventions":1891},[],[1870,1871],[1848,1873],{"intervention":1893,"totalTrials":94,"cells":1894},"Probiotic throat spray",{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1899,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1896,"activeCount":98},[],{"trials":1898,"activeCount":98},[],{"trials":1900,"activeCount":98},[],{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":98},[],{"trials":1906,"activeCount":98},[1907],{"nctId":1908,"briefTitle":1909,"status":267,"phases":1910,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":958,"conditions":1914,"interventions":1915},"NCT06057558","Airway Microbiome of Cystic Fibrosis Patients",[91],"2024-11-01","2025-11-01","2022-01-01",[911],[1893],{"intervention":1917,"totalTrials":94,"cells":1918},"Prilocaine",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1927,"NA":1929},{"trials":1920,"activeCount":98},[],{"trials":1922,"activeCount":98},[],{"trials":1924,"activeCount":98},[],{"trials":1926,"activeCount":98},[],{"trials":1928,"activeCount":98},[],{"trials":1930,"activeCount":98},[1931],{"nctId":1932,"briefTitle":1933,"status":246,"phases":1934,"primaryCompletion":1935,"completion":1935,"start":1936,"enrollment":1937,"conditions":1938,"interventions":1942},"NCT03219086","Spinal Prilocaine for Caesarian Sections",[91],"2022-05-01","2017-08-01",182,[1939,1917,1940,1941],"Combined Spinal Epidural Anesthesia","Bupivacaine","Pain",[1917,1940],{"intervention":1940,"totalTrials":94,"cells":1944},{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1951,"PHASE4":1953,"NA":1955},{"trials":1946,"activeCount":98},[],{"trials":1948,"activeCount":98},[],{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[1957],{"nctId":1932,"briefTitle":1933,"status":246,"phases":1958,"primaryCompletion":1935,"completion":1935,"start":1936,"enrollment":1937,"conditions":1959,"interventions":1960},[91],[1939,1917,1940,1941],[1917,1940],{"intervention":1962,"totalTrials":94,"cells":1963},"Microbiome spray",{"EARLY_PHASE1":1964,"PHASE1":1966,"PHASE2":1968,"PHASE3":1970,"PHASE4":1972,"NA":1974},{"trials":1965,"activeCount":98},[],{"trials":1967,"activeCount":98},[],{"trials":1969,"activeCount":98},[],{"trials":1971,"activeCount":98},[],{"trials":1973,"activeCount":98},[],{"trials":1975,"activeCount":98},[1976],{"nctId":1977,"briefTitle":1978,"status":1979,"phases":1980,"primaryCompletion":1981,"completion":1981,"start":1982,"enrollment":1127,"conditions":1983,"interventions":1986},"NCT04793997","Microbiome Therapy in Covid-19 Primary Care Support","SUSPENDED",[91],"2022-02-01","2021-02-01",[1984,1985],"SARS-CoV Infection","Corona Virus Infection",[1962],{"intervention":1988,"totalTrials":94,"cells":1989},"Antioxidantia",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1991,"activeCount":98},[],{"trials":1993,"activeCount":98},[],{"trials":1995,"activeCount":98},[],{"trials":1997,"activeCount":98},[],{"trials":1999,"activeCount":98},[],{"trials":2001,"activeCount":98},[2002],{"nctId":2003,"briefTitle":2004,"status":267,"phases":2005,"start":2006,"enrollment":616,"conditions":2007,"interventions":2010},"NCT01727492","Prevention of Noise-induced Damage by Use of Antioxidants",[91],"2012-11",[2008,2009],"Noise-induced Tinnitus","Noise-induced Hearing Loss",[1988],{"intervention":2012,"totalTrials":94,"cells":2013},"Patient-controlled intravenous analgesia",{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2015,"activeCount":98},[],{"trials":2017,"activeCount":98},[],{"trials":2019,"activeCount":98},[],{"trials":2021,"activeCount":98},[],{"trials":2023,"activeCount":98},[],{"trials":2025,"activeCount":98},[2026],{"nctId":2027,"briefTitle":2028,"status":246,"phases":2029,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":1625,"conditions":2033,"interventions":2034},"NCT03036514","Sublingual Sufentanil Tablet System (SSTS) Versus Intravenous Patient Controlled Analgesia After Back Surgery.",[91],"2019-08-01","2019-09-01","2017-04-05",[1767],[2012]]